Supernus Pharmaceuticals, Inc. (SUPN) P/E Ratio History
Historical price-to-earnings valuation from 2012 to 2025
Loading P/E history...
SUPN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Supernus Pharmaceuticals, Inc. (SUPN) trades at a price-to-earnings ratio of -75.7x, with a stock price of $51.45 and trailing twelve-month earnings per share of $-0.50.
The current P/E is 107% below its 5-year average of 1152.9x. Over the past five years, SUPN's P/E has ranged from a low of 8.6x to a high of 22261.5x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, SUPN trades at a 442% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, SUPN trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SUPN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SUPN P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $932M | 148.1 | - | +107% | |
| $4B | 9.4 | - | +68% | |
| $2B | 6.8Lowest | 0.66Best | +817%Best | |
| $6B | 25.3 | - | -22% | |
| $2B | 12.1 | - | +8% | |
| $6B | 63.6 | - | -33% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SUPN Historical P/E Data (2012–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $31.52 | $1.15 | 27.4x | -95% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $32.75 | $1.11 | 29.5x | -95% |
| FY2024 Q4 | $36.16 | $1.32 | 27.4x | -95% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $31.18 | $1.07 | 29.1x | -95% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $26.75 | $0.09 | 286.7x | -47% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $28.94 | $0.00 | 22261.5x | +4044% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $27.57 | $0.41 | 67.2x | -87% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $30.06 | $0.73 | 41.2x | -92% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $36.23 | $0.89 | 40.7x | -92% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $35.67 | $1.03 | 34.6x | -94% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $33.85 | $0.64 | 52.9x | -90% |
| FY2022 Q2 | $28.92 | $1.01 | 28.6x | -95% |
Average P/E for displayed period: 537.3x
See SUPN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SUPN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SUPN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSUPN — Frequently Asked Questions
Quick answers to the most common questions about buying SUPN stock.
Is SUPN stock overvalued or undervalued?
SUPN trades at -75.7x P/E, below its 5-year average of 1152.9x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SUPN's valuation compare to peers?
Supernus Pharmaceuticals, Inc. P/E of -75.7x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is SUPN's PEG ratio?
SUPN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2012-2025.